Synopsis

Source of validity: Scientific
Rating (out of 5): 2

Naringin, a flavonoid primarily found in grapefruit and other citrus fruits, has attracted interest for its potential cardiovascular benefits, including its effects on arteriosclerosis (the thickening and hardening of arterial walls). Preclinical studies provide some scientific support for naringin’s use in addressing arteriosclerosis. Animal models and in vitro experiments have shown that naringin can exert antioxidant, anti-inflammatory, and lipid-lowering effects, all of which are relevant to the pathophysiology of arteriosclerosis. For instance, research has demonstrated that naringin may reduce the formation of atherosclerotic plaques by inhibiting LDL oxidation, modulating inflammatory cytokines, and improving endothelial function (PubMed).

However, while these findings are promising, they are primarily limited to laboratory and animal studies. There are currently very few human clinical trials that specifically evaluate naringin for the prevention or treatment of arteriosclerosis. The evidence base is therefore rated as a 2 out of 5—indicating promising preclinical data, but insufficient direct clinical validation for routine use in humans. Naringin is not traditionally used as a folk remedy for arteriosclerosis, so its use is justified primarily by emerging scientific research rather than tradition. Further well-designed clinical trials are needed to confirm its efficacy and safety in this context.

More about naringin
More about Arteriosclerosis

Other ingredients used for Arteriosclerosis

Other health conditions supported by naringin

Products containing naringin